Abstract. The collagen gel droplet embedded culture-drug sensitivity test (CD-DST) is an anticancer drug sensitivity test developed about 10 years ago. This study reports the application of this test in the choice of neoadjuvant chemotherapy for the treatment of one patient with a large synovial sarcoma in the right shank. A 28-year old man presented at our hospital with a large mass in his right shank which had a hard texture and an obscure boundary. The histopathological diagnosis of excisional biopsy specimens was synovial sarcoma with low differentiation. Theprubicin/Cisplatin (THP/CDDP) neoadjuvant chemotherapy was selected based on the results obtained from the CD-DST. After three courses, a computed tomography (CT) scan was performed which indicated that the volume of the tumor had decreased significantly. Additionally, tumor necrosis, as well as the clinical response, showed complete response. The histopathological diagnosis of wide excision specimens indicated a grade III chemotherapy response. The patient was alive and without recurrence after a follow-up of 16 months. Our results indicated that the CD-DST is a useful tool for selecting neoadjuvant chemotherapeutic drugs for patients with synovial sarcoma.
Introduction
Synovial sarcoma is a type of malignant soft-tissue tumor that usually occurs in 80% of cases and affects knee and ankle joints in young adults. It also occurs in shoulder, elbow and hip regions. This neoplasm develops close to the joints, tendon sheaths and bursae, but it is rare for it to involve the synovial membrane. For the treatment of these tumors, the mainstay of curative therapy is the complete surgical resection of such tumor manifestations with negative histological margins. However, up to 50% of patients will develop distant metastases during the course of their disease (1) . Regional radiotherapy or adjuvant chemotherapy following surgery is therefore crucial. In certain cases, surgery is difficult to perform due to the large volume of the tumor, and then neoadjuvant chemotherapy is considered. A screening method for the selection of effective anticancer drugs for individual patients may be useful, particularly for patients who have large tumors and need neoadjuvant chemotherapy to decrease the volume of the tumor for local excision. The collagen gel droplet embedded culutre-drug sensitivity test (CD-DST) is an anticancer drug sensitivity test that requires only a small number of cells (3x10 3 per droplet) (2-4). The clinical usefulness of CD-DST for colon (5), breast (6) and gastric (7) cancers and even certain rare cases of solid tumors, such as ovarian mature cystic teratoma with malignant transformation to adenocarcinoma (8) , have been reported. Yabushita et al (9) found a strong correlation between clinical outcome and CD-DST results for anticancer drugs. This is a study of a case of a large synovial sarcoma in the right shank, for which neoadjuvant chemotherapy was investigated using CD-DST.
Materials and methods
Anticancer drugs. Isophosphamide (IFO) (10, 11) and anthracycline anti-tumor drugs (11, 12) , including therarubicin (THP), adriamycin (ADM) and epirubicin (EPI), are the first choice in the chemotherapy of soft tissue tumors. Cisplatin (CDDP) (13), vincristine (VCR) (13) and 5-fluorouracil (5-FU) Synovial sarcoma individual chemotherapy directed by collagen gel droplet embedded culture drug sensitivity test: A case report (14, 15) have also been reported to be effective against soft tissue tumors. CDDP, THP, VCR and 5-FU were examined in CD-DST. IFO has no effect in in vitro tests, and since it was necessary for IFO to be activated by phosphamidase in vivo, it was used as a negative control.
Preparation of the tumor cell suspension. The excisional specimen was minced finely using scissors, suspended in Hank's balanced saline solution (Hbss, gibco), treated with Dispersion Enzyme Cocktail EZ (including 1.0% collagenase; nitta gelatin, Inc., osaka, Japan) and digested at 37˚C for 1 h. The dispersed tumor cells were collected by centrifugation at 1000 rpm for 3 min, filtered through a 308 nm nylon mesh, washed in Hbss, suspended in PCM-1 medium (Nitta Gelatin) and then incubated in a collagen gel-coated flask (Cg-flask, nitta gelatin) in a Co 2 incubator at 37˚C for 24 h. The collagen gel in the Cg-flask was dissolved in a cell dispersion using EZ, and only viable cells that adhered to the collagen gel were collected and used for the sensitivity test.
Collagen gel droplet embedded culture-drug sensitivity test.
Type I collagen, 10X F-12 medium and reconstitution buffer (Cellmatrix Type CD, Nitta Gelatin) were combined in an ice bath at a ratio of 8:1:1. The prepared tumor cell suspension was added to a collagen solution (1:10, v:v) at a final density of 2x10 5 cells/ml. A total of three drops of the collagen-cell mixture (30 µl/drop) were placed in each well of a 6-well multiplate on ice and allowed to gel at 37˚C in a Co 2 incubator; the final concentration was ~3x10 3 cells/droplet. One hour later, each well was overlaid with 3 ml DMEM/F 12 medium (Gibco) containing 10% fetal bovine serum (Gibco, Canada), incubated in a CO 2 incubator at 37˚C overnight. CDDP, THP, VCR and 5-FU were then added to the final concentrations of 0.2 and 2.0 µg/ml, 0.02 and 0.2 µg/ml, 0.01 and 0.1 µg/ml and 1.0 and 10 µg/ml, respectively, followed by further incubation for 24 h. IFO (1 or 10 µg/ml) was added as a negative control.
In vitro chemosensitivity test. After removal of the medium containing the anticancer drugs, each well was rinsed twice with 3 ml Hbss, overlaid with 4 ml PCM-2 medium (serum Free Medium, Nitta Gelatin) and incubated for an additional 7 days. On the fourth day of incubation, the medium was changed. At the end of the incubation, neutral red (Nitta Gelatin) was added to each well at a final concentration of 50 µg/ml, and cells in the collagen gel droplets were stained for 2 h. Each collagen droplet was fixed with 10% neutral formalin buffer, washed in double-distilled water, air-dried and quantified using image analysis. The in vitro sensitivity was expressed as the percentage of the T/C ratio, where T is the total volume in the treated group and C is the total volume in the control group. When the T/C ratio was ≤50%, the in vitro drug sensitivity was regarded as effective. A T/C ratio of >50 and ≤60% was considered borderline, and a T/C ratio of >60% was considered to indicate a lack of efficacy (2). Clinical responses were assessed according to world Health Organization criteria, whereby tumors demonstrating a complete response or partial response are considered clinically responsive. The results of the CD-DST are shown in Fig. 4 .
Results
The patient was a 28-year-old male who presented with a large mass in the right shank. The perimeter of the right shank was 46.5 cm, while the left side was 37 cm (Fig. 1A) . Magnetic resonance imaging (MRI) revealed a 15x10x9 cm mass in the right shank ( Fig. 2A and b) , and a b-type Ultrasound scan showed a 1.0x0.7x0.5 cm intumesce in the right inguinal fold. The histopathological diagnosis of excisional biopsy specimens was synovial sarcoma with low differentiation (Fig. 3A) .
Although the tumor was extremely large for local excision, the patient refused to accept amputation of the right extremity. Neoadjuvant chemotherapy was considered in order to decrease the volume of the tumor to allow for a local excision. A sample of 0.5 g of the excisional specimen was used for the CD-DST test.
Neoadjuvant THP/CDDP chemotherapy was selected based on the results of the CD-DST (Fig. 4) , and administration of THP (30 mg/m 2 , d1-d2) and CDDP (40 mg/m 2 , d1-d2) was initiated. Upon completion of three courses of THP/CDDP chemotherapy, the perimeter of the right shank decreased from 46.5 to 42.5 cm, and its texture became much more supple. A precontrast CT scan showed that the volume of the tumor had decreased to 11x8.2 cm, while a contrast scan indicated tumor necrosis (Fig. 5A and b) and a b-type Ultrasound scan showed that the intumesce in the right inguinal fold had disappeared. Since the neoadjuvant THP/CDDP chemotherapy was successful, a local tumor excision was performed (Fig. 1b) . The pathodiagnosis indicated fibroblast cell proliferation and tumor cell necrosis as well as a grade III chemotherapy response (Fig. 3b) . Post-operatively, the patient received further adjuvant chemotherapy of THP/ CDDP, and he was alive and without recurrence at a 16-month follow-up.
Discussion
The first choice for the treatment of synovial sarcoma is local excision with wide margins of normal tissue, followed by regional radiotherapy or adjuvant chemotherapy (16, 17) . However, in some cases surgery is difficult to perform due to the large volume of the tumor, thus neoadjuvant chemotherapy is considered. In the case we reported, the tumor was extremely large and we were unable to perform a local excision. The patient involved was young and refused to accept amputation of the extremity. Neoadjuvant chemotherapy was therefore considered in order to decrease the volume of the tumor. IFO (10, 11) and anthracycline anti-tumor drugs (11, 12) , including THP, ADM and EPI, are the first choice in the chemotherapy of soft tissue tumors. CDDP (13), VCR (13) and 5-FU (14, 15) are also reported to be effective against soft tissue tumors. In this case, we used the system of CD-DST described by kobayashi et al (2-4) to check the sensitivity of tumor cells to THP, VCR, CDDP and 5-FU. since IFo should be activated by phosphamidase in vivo, we used it as the negative control. based on the results of the CD-DsT, THP/CDDP neoadjuvant chemotherapy was administered. Upon completion of three courses of THP/CDDP chemotherapy, the perimeter of the right shank decreased from 46.5 to 42.5 cm, the texture became much more supple, and a CT scan showed that the volume of the tumor had decreased from 15x10 to 11x8.2 cm and that the tumor necrosis had disappeared. A b-type Ultrasound scan showed that the intumesce in the right inguinal fold had also disappeared. The pathodiagnosis of the local excision specimen indicated fibroblast cell proliferation and tumor cell necrosis, as well as a grade III chemotherapy response (Fig. 3b) . The patient was alive and without recurrence at a 16-month follow-up evaluation. This clinical course therefore correlated successfully with the results of the CD-DST. Our results show that CD-DST can be used to evaluate anticancer drug sensitivity. Further investigation of CD-DST is required as a test for the prediction of anticancer drug sensitivity in cancer patients. CD-DST may therefore be particularly useful for selecting chemotherapeutic drugs for patients with synovial sarcoma, particularly for those with large tumors who require neoadjuvant chemotherapy to decrease the volume of the tumor prior to local excision surgery.
